Reaman G H, Ladisch S, Echelberger C, Poplack D G
Cancer. 1980 Jun 15;45(12):3090-4. doi: 10.1002/1097-0142(19800615)45:12<3090::aid-cncr2820451235>3.0.co;2-f.
One hundred twenty-five hematologic relapses of acute lymphoblastic leukemia (ALL) were treated with a four-drug reinduction regimen consisting of L-asparaginase, vincristine, daunomycin, and prednisone (Asp-VDP). Complete remission was achieved in 114 of 125 (91%) treatment courses. The regimen also proved to be highly effective in the management of multiple subsequent relapses which occurred in patients who had previously attained complete remissions with this regimen. The rates of remission induction for second and third reinduction attempts were 89% and 90%, respectively. Ten patients received this regimen for the treatment of four or more consecutive relapses and achieved complete remissions on each occasion. Toxicities related to therapy were not excessive. Although myelosuppression was the most frequently encountered toxicity, documented infection complicated only 14% of the treatment courses. These results constitute a considerable improvement in the management of recurrent ALL.
125例急性淋巴细胞白血病(ALL)血液学复发患者接受了由L-天冬酰胺酶、长春新碱、柔红霉素和泼尼松(Asp-VDP)组成的四药再诱导方案治疗。125个治疗疗程中有114个(91%)达到完全缓解。该方案在治疗先前使用此方案已达到完全缓解的患者发生的多次后续复发中也被证明非常有效。第二次和第三次再诱导尝试的缓解诱导率分别为89%和90%。10例患者接受该方案治疗连续4次或更多次复发,每次均实现完全缓解。与治疗相关的毒性并不严重。虽然骨髓抑制是最常遇到的毒性,但记录在案的感染仅使14%的治疗疗程复杂化。这些结果在复发性ALL的治疗方面有了相当大的改善。